Introduction to the Indian version of drug information for lenvatinib/lenvatinib

The Indian version of Lenvatinib/Lenvatinib (Lenvatinib) is a drug version made by the Indian NATCO Pharmaceutical Company based on the original drug Lenvima (produced by Japan's Eisai Company). It has the same active ingredient Lenvatinib mesilate. The research and development of generic drugs follows strict bioequivalence standards, and their efficacy and safety are basically the same as those of the original drugs. The Indian version of lenvatinib is widely used in the international market due to its low production cost and affordable price, and is especially concerned by cancer patients in developing countries.

Currently, the common specifications of lenvatinib on the Indian market are 4mg and 10mg packages. The price of 4mg 30 tablets is about RMB 400more than RMB, and the price of 10mg 30 tablets is about more than 1,000RMB (affected by exchange rate fluctuations). In comparison, the price of the original drug Lenvima in places such as the United States and Japan is often more than RMB 2,000, so the Indian version has obvious economic advantages.

It is worth noting that although the chemical composition of the Indian version of lenvatinib is the same as the original drug, it cannot be purchased through hospital channels in China because it has not been officially registered and approved by ChinaNMPA. Some patients choose to obtain drug supply through regular overseas pharmacies or cross-border medical institutions. This method needs to ensure legal channels, complete packaging, and reliable sources.

From the perspective of drug efficacy, the Indian version of lenvatinib is stable in clinical use, and its multi-target inhibitory mechanism is consistent with the original drug, which can inhibit tumor angiogenesis and delay tumor spread. Some doctors pointed out that the metabolic characteristics of generic drugs and original drugs are basically the same, so the difference in actual efficacy is small.

Indian pharmaceutical companies have rich experience in the field of generic drug research and development and are highly recognized in the international medical community. For patients who require long-term medication, the Indian version of lenvatinib provides a relatively affordable and sustainable treatment option, especially in non-medical insurance treatment or adjuvant treatment scenarios, the cost-effectiveness is more outstanding.

Reference materials:https://www.lenvima.com/